The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study
Open Access
Abstract
Since 2019, the coronavirus disease 2019 (COVID-19) global pandemic has caused more than 300 million cases of disease and 5 million deaths. Vaccination has been widely accepted as the most effective measure for the prevention and control of this disease. However, there is little understanding about serum anti-SARS-CoV-2 IgM/IgG levels after inactivated vaccination as well as the relationship with peripheral blood leukocytes in the non-COVID-19 infected population. A total of 16,335 male and 22,302 female participants were recruited in this study, which was conducted in the Peking University Third Hospital located in Beijing (China). The level and seroprevalence of serum anti-SARS-CoV-2 receptor-binding domain (RBD) IgM/IgG and the association with peripheral blood leukocytes classification were investigated. With an increase in the number and percentage of full immunization of COVID-19 vaccinations in Beijing, serum anti-SARS-CoV-2 IgG antibodies levels and seroprevalence were significantly elevated (p < 0.01). The serum anti-SARS-CoV-2 IgG antibodies of 60 years and older persons were significantly lower than that of individuals that are 18~60 years old (p < 0.01), and there was a positive relationship between serum anti-SARS-CoV-2 IgG antibodies levels and peripheral blood lymphocyte count. The investigation of serum anti-SARS-CoV-2 IgM/IgG antibodies and the peripheral hematological index may prompt and help understand the adaptive immune response of vaccination.Keywords
Funding Information
- National Natural Science Foundation of China (81673118, 81971313 and 62071011)
- Talents Incubation Projects of Peking University Third Hospital (BYSYFY2021035)
This publication has 30 references indexed in Scilit:
- SARS-CoV-2 Antibodies and Associated Factors at Different Hospitalization Time Points in 192 COVID-19 CasesThe Journal of Applied Laboratory Medicine, 2021
- Real-world experience of SARS-CoV-2 antibody assays in UK healthcare workersClinical Medicine, 2021
- Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional studyThe Lancet, 2021
- Neglected tropical diseases activities in Africa in the COVID-19 era: the need for a “hybrid” approach in COVID-endemic timesInfectious Diseases of Poverty, 2021
- Seroprevalence of SARS‐CoV‐2 infections among children visiting a hospitalPediatric Investigation, 2020
- Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infectionmedRxiv, 2020
- Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological AssaysClinical Chemistry, 2020
- Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT)Annals of Medicine, 2020
- The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsScience Immunology, 2020
- Evaluation of Routine Blood Tests for Diagnosis of Suspected Coronavirus Disease 2019Clinical Laboratory, 2020